PET-Guided Response Assessment and Risk-Adapted Therapy in Hodgkin's Lymphoma
This information was originally presented on September 21, 2013, at the NCCN 8th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- List the various PET response criteria for interim response assessment
- Discuss the prognostic significance of early interim PET scans in patients with early stage and advanced stage HL
Craig H. Moskowitz, MD
Memorial Sloan-Kettering Cancer Center
- 0.50 Participation
- 0.44 Nurse
- 0.50 Pharmacist
- 0.50 Physician